New hope for aggressive breast cancer: two chemo cocktails face off in clinical trial
NCT ID NCT04159142
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 2 trial is testing two different chemotherapy combinations in 414 women with advanced triple-negative breast cancer (TNBC), a fast-growing type that lacks common treatment targets. One group gets nab-paclitaxel plus carboplatin, the other gets nab-paclitaxel plus capecitabine. The goal is to see which combo works better at slowing the cancer's growth and improving survival, while monitoring side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nab-paclitaxel plus carboplatin or capecitabine
What this could lead to
If successful, this could identify a more effective chemotherapy combination for advanced triple-negative breast cancer, potentially improving survival and delaying disease progression.
What could go wrong
This is a Phase 2 trial, so results are still early. Chemotherapy can cause significant side effects, and the benefit may be modest or not confirmed in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Fourth Hospital of Hebei Medical University
RECRUITINGShijiazhuang, Hebei, 050011, China
Contact Phone: •••-•••-•••• Email: •••••@•••••